Thomas Meier
Fondatore presso SANTHERA PHARMACEUTICALS HOLDING AG
Patrimonio netto: 34 003 $ in data 31/05/2024
Profilo
Dr. Thomas Meier is a Chairman at Santhera Pharmaceuticals Holding AG and a Managing Partner at Viopas Venture Consulting GmbH.
He is on the Board of Directors at Onconetix, Inc., Visgenx, Inc. and Novaremed AG.
Dr. Meier was previously employed as a Chief Executive Officer by MyoContract AG and a Chairman by PharmaBiome AG.
He received his graduate degree from the University of Basel and a doctorate degree from the University of Basel.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2023 | 3 108 ( 0.02% ) | 34 003 $ | 31/05/2024 |
Posizioni attive di Thomas Meier
| Società | Posizione | Inizio |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Fondatore | 07/09/2004 |
| ONCONETIX, INC. | Direttore/Membro del Consiglio | 06/02/2024 |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Direttore/Membro del Consiglio | 01/05/2020 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Corporate Officer/Principal | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | 01/01/2022 |
Precedenti posizioni note di Thomas Meier
| Società | Posizione | Fine |
|---|---|---|
PharmaBiome AG
 PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Presidente | 01/01/2021 |
| MyoContract AG | Amministratore Delegato | 01/01/2004 |
Formazione di Thomas Meier
| University of Basel | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| ONCONETIX, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
| MyoContract AG | Health Technology |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Thomas Meier
